Item | Newly Diagnosed Patients (95% CI) | Previously Diagnosed Patients (95% CI) | Total (95% CI) | |||
DST | 193 (100%) | - | 17 (100%) | - | 210 (100%) | |
Sensitive to all | 150 (77.7%) | 78.3 - 81.3 | 5 (29.4%) | 155 (73.8%) | 70.1 - 79.1 | |
Mono Resistance TB | ||||||
Isoniazid (H) | 30 (16.0%) | 21.1 - 24.6 | 7 (41.2%) | 1.1 - 10.6 | 37 (17.6%) | 24.5 - 28.0 |
Rifampicin (R) | 4 (2.1%) | 3.31 - 7.20 | 4 (23.5%) | 1.54 - 1.99 | 8 (3.8%) | 4.8 - 11.8 |
Ethambutol (E) | 20 (10.0%) | 23.2 - 26.7 | 9 (52.9%) | 1.21 - 4.74 | 29 (13.8%) | 25.4 - 28.9 |
Streptomycin (S) | 18 (18.3%) | 24.4 - 30.8 | 10 (58.8%) | 1.15 - 1.67 | 28 (13.3%) | 29.8 - 33.2 |
Multi-Drug Resistance TB (MDRTB) | ||||||
H + R | 4 (2.1%) | 2.2 - 6.1 | 4 (23.5%) | 1.54 - 1.99 | 8 (3.8%) | 3.8 - 7.7 |
H + R + E | 1 (0.5%) | 0.3 - 0.7 | 1 (5.9%) | 1.82 - 2.07 | 2 (1.0%) | 1.0 - 3.0 |
H + R + S | - | - | - | - | - | - |
H + R + E + S | - | - | - | - | - | - |
Total MDR-TB | 5 (2.6%) | 1.7 - 3.4 | 5 (29.4%) | 25.6 - 32.7 | 10 (4.8%) | 3.8 - 6.1 |
Other resistance patterns | ||||||
H + E | 11 (5.7%) | 3.8 - 7.7 | 3 (17.6%) | 1.62 - 2.03 | 14 (6.7%) | 4.8 - 8.7 |
H + S | 7 (3.6%) | 1.7 - 5.0 | 3 (17.6%) | 1.62 - 2.03 | 10 (4.8) | 2.9 - 6.8 |
H + E + S | 2 (1.0%) | 0.98-3.0 | - | - | 2 (1.0%) | 2.0 - 3.0 |
R + E | 2 (1.0%) | 0.98 - 3.0 | 2 (11.8%) | 1.71 - 2.05 | 4 (1.9%) | 1.1 - 3.9 |
E + S | 11 (5.7%) | 3.7 - 7.7 | 1 (5.9%) | 1.82 - 2.03 | 12 (5.7%) | 3.8 - 3.9 |
R + S | 5 (2.6%) | 0.65 - 4.6 | - | - | 5 (2.4%) | 2.0 - 4.3 |
R + E + S | - | - | - | - | - | - |